Skip to Page Content

FREE PREVIEW | Subscribers get full access to this article:   Free Trial »   Subscribe »

The Pink Sheet Daily

With U.S Approval, EUSA Set To Prove Value of Transatlantic Spec Pharma Model – And Orphan Focus


Executive Summary

U.S approval of orphan drug Erwinase puts specialty pharma firm EUSA on new growth trajectory, showing the value of its strategy to build a transatlantic infrastructure for niche products – and transitioning it from a commercially-focused to a development-capable organization.


Purchase this Article

$85.00   Buy Now


For $85.00, purchase this 1576-word article and receive immediate online access. 100% Satisfaction Guarantee.

View a complete sample article »

Already a Subscriber?

Log in for complete access.

Log In


Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.